Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › axicabtagene ciloleucel

axicabtagene ciloleucel

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of axicabtagene ciloleucel

9 trials tracked of axicabtagene ciloleucel: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 56 citations.

9Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 3 1 Phase 2 7
  1. Phase 3 Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma Completed · 56 cited
  2. Phase 4 Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting Completed
  3. Phase 2 A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity Completed
  4. Phase 2 Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2) Completed
  5. Phase 2 Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma Completed
  6. Phase 2 A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Completed
Show 3 more trials
  1. Phase 2 Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma Completed
  2. Phase 2 Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma Completed
  3. Phase 2 Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma Completed

Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Axicabtagene ciloleucel shows higher early response but greater toxicity than tisagenlecleucel in large B-cell lymphoma
Oncology Meta-analysis
Axicabtagene ciloleucel shows higher early response but greater toxicity than tisagenlecleucel in large B-cell lymphoma Comparison of two CAR-T cell therapies for lymphoma
This meta-analysis compared axicabtagene ciloleucel and tisagenlecleucel for the treatment of large B-cell lymphoma. While axicabtagene cilo…
New data comparing axicabtagene ciloleucel and tisagenlecleucel shows different levels of early response and safety risks for lymphoma patie…
Jul 12, 2026
One-step no-wash flow cytometry improved CAR-T expansion detection compared to classical two-step methods in a cohort study
Oncology Cohort
One-step no-wash flow cytometry improved CAR-T expansion detection compared to classical two-step methods in a cohort study New Test Lets Doctors See CAR-T Cells Faster
This cohort study evaluated a one-step no-wash flow cytometry method against a classical two-step protocol in 29 patients receiving autologo…
A new lab method helps doctors watch CAR-T cells in real time to catch side effects early and ensure the therapy is working.
Frontiers Apr 13, 2026